Propelx Logo
  • For Investors
  • For Founders
  • Portfolio
  • Insights
    • Podcast
    • Events
    • Blog
    • Glossary
    • Newsletter
    • Infographics
    • Angel Resources
  • Investor Login
  • Sign up to invest
  • For Investors
  • For Founders
  • Portfolio
  • Insights
    • Podcast
    • Events
    • Blog
    • Glossary
    • Newsletter
    • Infographics
    • Angel Resources
  • Investor Login
  • Sign up to invest
  • Investor Login
  • Sign up to invest

Propel(x) Industry Council

Industry leaders are a crucial part of driving innovation and supporting emerging startups. Access to established players in industry is crucial to startup success and Propel(x) is building the Propel(x) Industry Council to connect the startups fundraising on our platform to the industry players that will provide mentorship, help build key customer relationships, and invest in our startups. Have questions? Contact us

  • ARM

    ARM technology is at the heart of a computing and connectivity revolution that is transforming the way people live and businesses operate. From the unmissable to the invisible; our advanced, energy-efficient processor designs are enabling the intelligence in 90 billion silicon chips and securely powering products from the sensor to the smartphone to the supercomputer. With more than 1,000 technology partners including the world’s most famous business and consumer brands, we are driving ARM innovation into all areas compute is happening inside the chip,the network and the cloud. We are looking for disruptive technology innovations in IoT and AI.

     

  • Bio Rad

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer care, serving more than 100,000 research and healthcare industry customers through its global network of operations. Bio-Rad is interested in startup companies with innovative products and technologies for the life science research, food safety and diagnostics markets.

     

  • Bosch

    Bosch is a multinational engineering and electronics company. Our products and services focus on Mobility solutions, Industrial Technologies, Consumer Goods and Energy & Building Technologies. Robert Bosch Venture Capital invests in seed, early-, and late-stage Venture Capital rounds of privately held companies that are strategically aligned with objectives of Bosch.We look to build deeper connections with companies in the following areas: Automation and Electrification, Energy Efficiency, Enabling Technologies, Healthcare and Service/Business Models.

  • CareDx

    CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions.

  • Boston Scientific

    Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare.

  • Chevron

    Chevron Technology Ventures (CTV) champions the innovation, commercialization and integration of emerging technologies into Chevron. We pursue innovative business solutions and externally developed technologies that have the potential to improve Chevron’s base business operations and champion their deployment and adoption into Chevron.

  • MilliporeSigma

    MilliporeSigma is a leading science and technology company in healthcare, life sciences and performance materials. From drug discovery and development to manufacturing and diagnostics, we are dedicated to solving the toughest problems in life science by collaborating with the global scientific community. Our 300,000 products range from lab water systems to gene editing tools, antibodies, cell lines and end-to-end systems to manufacture drugs. We work closely with our customers from academia, biotech and pharma to help deliver the promise of their work better, faster and safer. Before researchers can make scientific breakthroughs, they need state-of-the-art tools, services and expertise to perform experiments and engineer new products. At MilliporeSigma, that’s where we come in. In 2015, EMD Millipore joined forces with Sigma-Aldrich. Our combined organization, which operates as MilliporeSigma in the United States and Canada, is a global leader in the life science business.

  • Merck Ventures

    Merck Ventures BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany (known as M Ventures in the United States), is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck’s core business areas. From our headquarters in Amsterdam and offices in the U.S. and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

  • Schneider Electric

    Schneider Electric is the leading provider of energy efficiency and automation solutions for commercial, industrial and home applications. We are looking for innovations in the areas of:

    – augmented operations: deep learning, AI/ML, predictive analytics to enhance smart operations of buildings, factories, hospitals, data centers, and other facilities
    – smart home: energy efficiency solutions, including EV charging, inverters, smart devices and systems
    – smart building: from hotels to hospitals to offices, we are looking to improve the way assets are used more efficiently

  • Simcere

    Simcere is a leading Chinese pharmaceutical company which manufactures and sells ~50 anti-tumor, cardiovascular, anti-infection, rheumatism and other drugs in China and select European markets. Since it was first established in 1995, the company has pursued a growth strategy of R&D, M&A, and international collaboration – including jointly developing the world’s first anti-VEGF humanized monoclonal antibody products with Apexigen, and anti-tumor drugs with Bristol-Myers Squibb. As a pioneer in the forefront of healthcare, Simcere’s mission is to identify and provide more effective drugs to patients.

Council Member Benefits

  • Stay updated on the latest innovation in your industry
  • Mentor founders and help grow startups
  • Source deals on the cutting edge of your field
Become a Council Member

Startup Benefits

  • Connect with potential customers and partners
  • Access mentorship and coaching by industry leaders
  • Attract and engage with strategic investors
Get Intro to Members
  • ABOUT US
    • Company
    • Press Room
    • Industry Council
    • Channel Partners
    • Careers
  • How it works
    • Invest
    • Raise
    • FAQs
  • JOIN
    • Investors
    • Founders
  • Learn
    • Podcast
    • Events
    • Blog
    • Glossary
    • Newsletter
    • Infographics
    • Angel Resources
  • LEGAL
    • Terms of Use
    • Privacy Policy
    • Hubble Investments Privacy Notice
    • Business Continuity Plan
    • Form CRS
    • Conversation Starters

© 2022 PROPEL(X) - All Rights Reserved.

Propel(x) is an EvoNexus FinTech Incubator portfolio company.

  • How to Become an Angel Investor
  • Angel Investing Tips
  • How to Evaluate Startups
  • Portfolio Diversification

This site is operated by Propel(x) Inc. (“Propel(x)”), which is not a registered broker dealer. Propel(x) does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities posted here are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. Propel(x) has not taken steps to verify the adequacy, accuracy, or completeness of the information. Neither Propel(x) nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind related to the adequacy, accuracy or completeness of any information on this site or the use of information on this site. By accessing this site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

Certain offerings posted on the platform and so designated are offered by Hubble Investments, Member FINRA / SIPC and an affiliate of Propel(x), located at 1 Franklin Parkway, Bldg # 930/1 - Fintech Suite, San Mateo CA 94403. Hubble Investments does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform. This website is intended solely for qualified investors. Private investments are highly illiquid and risky and are not suitable for all investors. Investments in early-stage private companies should only be part of your overall investment portfolio. Furthermore, the allocation to this asset sub-class may be best fulfilled through a balanced portfolio of different start-ups. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.

scroll top arrow